WNT3A and prostate carcinoma: In cancer, WNT16B is a driver of resistance to cytotoxic chemotherapy in prostate cancer (Sun et al, 2012), PARP1 is high in colorectal cancer (Dörsam et al, 2018), and WNT3A expression is a cause of in vitro olaparib resistance in an ovarian cancer cell line (Yamamoto et al, 2019).